Skip to main content

Table 2 Main characteristics of studies included in this meta-analysis

From: Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies

First author

Publication year

Case nationality

Dominant ethnicity

Median or mean age

Study design

Malignant disease

Main type of pathology

Detected sample

Assay method

Survival analysis

Source of HR

Maximum months of follow-up

Chou [20]

2018

China

Asian

50

R

Glioblastoma multiforme

Glioma

Tissue

ihc

OS/PFS

Reported

207

Lu [10]

2017

China

Asian

60

R

Colorectal cancer

AdenoCa

Tissue

ihc

OS

SC

40

Huang [4]

2017

China

Asian

60

R

Colorectal cancer

AdenoCa

Tissue

ihc

OS

Reported

50

Li [11]

2017

China

Asian

40

R

Cervical carcinoma

SqCa

Tissue

ihc

OS

Reported

78

Shimuraa [41]

2017

Japan

Asian

55

R

Biliary cancer

AdenoCa

Serum

ELISA

OS

Reported

69.9

Shimurab [41]

2017

Japan

Asian

55

R

Pancreatic cancer

AdenoCa

Serum

ELISA

OS

Reported

66

Wang [49]

2017

China

Asian

NM

R

Ovarian cancer

SqCa

Tissue

ihc

OS

Reported

72

Liu [37]

2017

China

Asian

65.1

R

Colorectal cancer

AdenoCa

Tissue

ihc

DFS

Reported

60

Gopalan [21]

2016

Australia

Caucasian

60

R

Colorectal cancer

AdenoCa

Tissue

ihc

OS

SC

110

Ilmer [12]

2016

American

Caucasian

47

R

Breast cancer

AdenoCa

Tissue

ihc

OS

SC

232

Yang [48]

2016

China

Asian

66.8

R

Colorectal cancer

AdenoCa

tissue

ihc

DFS

Reported

60

Tas [36]

2016

Turkey

Caucasian

59.5

R

Gastric cancer

AdenoCa

Serum

ELISA

OS

SC

97

Cheng [40]

2015

China

Asian

55.2

R

Gastric cancer

AdenoCa

Serum

ELISA

OS

SC

60

Lu [47]

2015

China

Asian

51

R

Ovarian cancer

SqCa

Tissue

ihc

OS

Reported

77

Jiang [22]

2014

China

Asian

50

R

Hepatocellular carcinoma

AdenoCa

Tissue

ihc

OS

Reported

87

Gomes [23]

2014

Brazil

Caucasian

50

R

Gastric cancer

AdenoCa

Tissue

ihc

OS

SC

55

Mu [44]

2013

China

Asian

66

R

Gastric cancer

AdenoCa

Tissue

ihc

OS

Reported

NM

Wu [45]

2013

China

Asian

59.6

R

Non-small cell lung cancer

SqCa

Tissue

ihc

OS

Reported

90

Liu [46]

2013

China

Asian

57.1

R

Non-small cell lung cancer

SqCa

Tissue

ihc

OS

SC

80

Yamaki [24]

2012

Japan

Asian

53

R

Breast cancer

AdenoCa

Tissue

ihc

OS/PFS

SC

13

Yang [25]

2012

China

Asian

45

R

Gallbladder carcinoma

AdenoCa

Tissue

ihc

OS

SC

18

Kim [26]

2012

Korea

Asian

60

R

Gastric cancer

AdenoCa

Tissue

ihc

OS

Reported

96

Kosacka [38]

2011

Poland

Caucasian

59.3

R

Non-small cell lung cancer

SqCa

Tissue

ihc

OS

SC

24

Povegliano [27]

2010

Brazil

Caucasian

50

R

Colorectal cancer

AdenoCa

Tissue

ihc

OS

SC

83

Canesin [42]

2010

American

Caucasian

NM

R

Bladder cancer

SqCa

Tissue

ihc

OS

SC

173

Vereecken [43]

2009

American

Caucasian

60

R

Melanoma

NM

Serum

ELISA

OS

Reported

60

Miranda [28]

2009

Brazil

Caucasian

59

R

Laryngeal carcinoma

SqCa

Tissue

ihc

DFS

SC

166

Szoke [29]

2007

German

Caucasian

58.8

R

Non-small cell lung cancer

SqCa

Tissue

ihc

OS

SC

127

Kang [30]

2007

Korea

Asian

63

R

Esophageal cancer

SqCa

Tissue

ihc

OS

SC

108

Moisa [39]

2007

Germany

Caucasian

56.8

R

Breast cancer

AdenoCa

Tissue

ihc

OS/DFS

Reported

185

Okada [13]

2006

Japan

Asian

63.9

R

Gastric cancer

AdenoCa

tissue

ihc

OS

Reported

72

Plzak [31]

2004

Prague

Caucasian

60

R

Head and neck carcinoma

SqCa

Tissue

ihc

OS

SC

60

Piantelli [14]

2002

Rome

Caucasian

60

R

Laryngeal carcinoma

SqCa

Tissue

ihc

OS/RFS

SC

90

Brule [32]

2000

Belgium

Caucasian

65

R

Prostate carcinomas

AdenoCa

Tissue

ihc

PFS

SC

86

Honjo [33]

2001

Japan

Asian

60

R

Tongue carcinoma

SqCa

Tissue

ihc

OS/DFS

SC

118

Nakamura [34]

1999

Japan

Asian

NM

R

Colorectal cancer

AdenoCa

Tissue

ihc

OS/DFS

SC

103

Sanjuan [35]

1997

Spain

Caucasian

NM

R

Colorectal cancer

AdenoCa

Tissue

ihc

OS/RFS

SC

96

  1. R retrospective, AdenoCa adenocarcinoma, SqCa squamous carcinoma, IHC immunohistochemistry, OS overall survival, DFS disease-free survival, PFS progression-free survival, RFS recurrence-free survival, SC survival curve
  2. a, bData extracted from one study due to different malignant disease (biliary cancer and pancreatic cancer)